Our findings therefore suggest that the elevated RGS2 expression in SARS-CoV-2 positive nasopharyngeal cells is implicated in the common anosmia or reduced olfaction observed in many COVID-19 patients. This evidence concerns the gene RGS2 and COVID-19.